Schizophrenia Drugs Market Size to Reach USD 9.48 Billion by 2026; Launch Of PERSERIS (Risperidone) By Indivior PLC Will Aid Growth

The schizophrenia drugs market size is expected to gain impetus from the increasing adoption of advanced schizophrenia drugs in emerging markets, says Fortune Business Insights in a report, titled “Schizophrenia Drugs Market Size, Share & Industry Analysis, By Therapeutic Class (Second Generation, Third Generation, Others), By Treatment (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) and Regional Forecast, 2019-2026.”According to Fortune Business Insights, the global schizophrenia drugs market was valued at USD 6.75 Billion in 2018 and is expected to reach USD 9.48 Billion by 2026 at a CAGR of 4.3%.

According to the report published by Fortune Business Insights, North America is expected to dominate the global schizophrenia drugs market during the forecast period owing to the rapid adoption of advanced schizophrenia drugs.

Increasing demand for efficient drugs will further augment the growth of the global schizophrenia drugs market in North America. In addition, the global schizophrenia drugs market Europe is expected to witness significant growth during the forecast period owing to the strong R&D initiatives in countries such as Germany, the U.K., and France.

The report provides all-inclusive information on the schizophrenia drugs industry. The study focuses on the fundamental developments and changes in the global schizophrenia drugs market and also offers statistic data on regions and other segments of the market. The report suggests methods and approaches for companies operating in the schizophrenia drugs market; to gain traction for their businesses.

Rising Number Of Schizophrenic Patients Will Foster Growth

According to Fortune Business Insights, the robust pipeline for schizophrenia drugs will boost the global schizophrenia drugs market revenue during the forecast period. The growing number of schizophrenic patients and healthcare institutes for advanced mental treatment will enable the growth of the global schizophrenia drugs market. For instance, in the U.S., federal and state laws require that the reimbursements for mental healthcare be at parity with the physical healthcare reimbursements. Furthermore, the increasing need for advanced and effective treatment will uplift the schizophrenia drugs market shares during the forecast period.

Approval for PERSERIS (risperidone) Will Enable Growth

Indivior PLC, a renowned name in the pharmaceutical industry announced the launch of PERSERIS after receiving approval from the Food and Drug Administration (FDA). PERSERIS is the first once-monthly subcutaneous risperidone-containing, long-acting injectable (LAI) for the treatment of schizophrenia in adults. The launch of PERSERIS will favor growth to the global schizophrenia drugs market owing to the extended-release delivery system to form a subcutaneous (under the skin) depot that provides sustained levels of risperidone over one month.

Rising Awareness Regarding Schizophrenia Drugs Will Boost Growth in North America

According to the report, the schizophrenia drugs market in North America generated a revenue of USD 4.19 Billion in 2018 and is expected to remain dominant during the forecast period owing to the rapid adoption of advanced schizophrenia drugs across the region. Furthermore, increasing awareness regarding advanced drugs for the treatment of schizophrenia will stimulate growth in the region. In addition, increasing demand for efficient drugs and a growing number of schizophrenic patients are expected to accelerate the schizophrenia drugs market growth in North America.

Browse Complete report Details: https://www.fortunebusinessinsights.com/industry-reports/schizophrenia-drugs-market-101531

The Global Schizophrenia Drugs Market Is Segmented into: